MACK - Merrimack Pharmaceuticals: SCLC Presents A Lower Hurdle For Approval Than Initially Assumed
The opportunity
Our previous article highlighted the attractive specialty investment opportunity presented by Merrimack Pharmaceuticals (MACK) relative to their regulatory approval-based milestone payments for Onivyde (the liposomal formulation of irinotecan). We will publish follow up pieces analyzing each of the potential milestones in more depth. We will start with 2nd line SCLC, as we believe that this will be the first clinical study to read out.
According to the most recent quarterly filings, MACK is eligible to receive $150.0 million upon receiving FDA approval for Onivyde for the treatment of SCLC after